$1.66
-0.02-0.97%
Last update: 9:28 AM
15 minutes delayed
Comments
Loading...
Ikena Oncology
IKNANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Ikena Oncology (NASDAQ:IKNA) Stock, Analyst Ratings, Price Targets, Forecasts
Ikena Oncology Inc has a consensus price target of $13.6 based on the ratings of 5 analysts. The high is $27 issued by Credit Suisse on August 13, 2021. The low is $2 issued by Wedbush on May 29, 2024. The 3 most-recent analyst ratings were released by Wedbush, HC Wainwright & Co., and Wedbush on May 29, 2024, May 29, 2024, and May 14, 2024, respectively. With an average price target of $4.67 between Wedbush, HC Wainwright & Co., and Wedbush, there's an implied 181.33% upside for Ikena Oncology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Credit Suisse
HC Wainwright & Co.
Credit Suisse
1calculated from analyst ratings
Analyst Ratings for Ikena Oncology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/29/2024 | Buy Now | 20.57% | Wedbush | David Nierengarten | $8 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 05/29/2024 | Buy Now | 141.14% | HC Wainwright & Co. | Andres Maldonado | $11 → $4 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 382.28% | Wedbush | David Nierengarten | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/19/2024 | Buy Now | 563.13% | HC Wainwright & Co. | Andres Maldonado | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 563.13% | HC Wainwright & Co. | Andres Maldonado | $11 → $11 | Maintains | Buy | Get Alert |
| 01/19/2024 | Buy Now | 382.28% | Wedbush | David Nierengarten | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 01/19/2024 | Buy Now | 563.13% | HC Wainwright & Co. | Andres Maldonado | → $11 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 563.13% | HC Wainwright & Co. | Andres Maldonado | $18 → $11 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | 563.13% | Wedbush | David Nierengarten | → $11 | Initiates | → Outperform | Get Alert |
| 08/10/2023 | Buy Now | 985.12% | HC Wainwright & Co. | Andres Maldonado | → $18 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 985.12% | HC Wainwright & Co. | Andres Maldonado | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 985.12% | HC Wainwright & Co. | Andres Maldonado | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 683.7% | Credit Suisse | Judah Frommer | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 985.12% | HC Wainwright & Co. | Andres Maldonado | → $18 | Assumes | → Buy | Get Alert |
| 03/17/2023 | Buy Now | 1226.26% | HC Wainwright & Co. | Robert Burns | → $22 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 683.7% | Credit Suisse | Judah Frommer | $16 → $13 | Maintains | Outperform | Get Alert |
| 11/29/2022 | Buy Now | 864.55% | Credit Suisse | Judah Frommer | $18 → $16 | Maintains | Outperform | Get Alert |
| 11/29/2022 | Buy Now | 1226.26% | HC Wainwright & Co. | Robert Burns | $26 → $22 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 985.12% | Credit Suisse | Judah Frommer | $20 → $18 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 1105.69% | Credit Suisse | Judah Frommer | $24 → $20 | Maintains | Outperform | Get Alert |
| 04/13/2022 | Buy Now | 1467.4% | HC Wainwright & Co. | Robert Burns | $25 → $26 | Maintains | Buy | Get Alert |
| 12/23/2021 | Buy Now | 1407.11% | HC Wainwright & Co. | Robert Burns | → $25 | Initiates | → Buy | Get Alert |
| 08/13/2021 | Buy Now | 1527.68% | Credit Suisse | — | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Ikena Oncology (IKNA) stock?
The latest price target for Ikena Oncology (NASDAQ:IKNA) was reported by Wedbush on May 29, 2024. The analyst firm set a price target for $2.00 expecting IKNA to rise to within 12 months (a possible 20.57% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ikena Oncology (IKNA)?
The latest analyst rating for Ikena Oncology (NASDAQ:IKNA) was provided by Wedbush, and Ikena Oncology downgraded their neutral rating.
When was the last upgrade for Ikena Oncology (IKNA)?
There is no last upgrade for Ikena Oncology
When was the last downgrade for Ikena Oncology (IKNA)?
The last downgrade for Ikena Oncology Inc happened on May 29, 2024 when Wedbush changed their price target from $8 to $2 for Ikena Oncology Inc.
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on May 29, 2024 so you should expect the next rating to be made available sometime around May 29, 2025.
Is the Analyst Rating Ikena Oncology (IKNA) correct?
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a downgraded with a price target of $8.00 to $2.00. The current price Ikena Oncology (IKNA) is trading at is $1.66, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.